Advances in immunotherapy, which could extend the lives of people with cancers such as asbestos-related mesothelioma, could lead to a problem for run-off players, a legacy conference has been told.
Advances in immunotherapy, which could extend the lives of people with cancers such as asbestos-related mesothelioma, could lead to a problem for run-off players, a legacy conference has been told.